Blood Reviews最新文献_第5页

Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management 免疫缺陷/失调-相关淋巴组织增生性疾病。修订分类和管理

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101167

Antonino Carbone , Amy Chadburn , Annunziata Gloghini , Emanuela Vaccher , Mark Bower

{"title":"Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management","authors":"Antonino Carbone , Amy Chadburn , Annunziata Gloghini , Emanuela Vaccher , Mark Bower","doi":"10.1016/j.blre.2023.101167","DOIUrl":"10.1016/j.blre.2023.101167","url":null,"abstract":"<div><p>Significant advances in the field of lymphoma have resulted in two recent classification proposals, the International Consensus Classification (ICC) and the 5th edition WHO. A few entities are categorized differently in the ICC compared to the WHO. Nowhere is this more apparent than the immunodeficiency lymphoproliferative disorders<span>. The three previous versions of the WHO classification (3rd, 4th and revised 4th editions) and the ICC focused on four clinical settings in which these lesions arise for primary categorization. In contrast the 2023 WHO 5th edition includes pathologic characteristics including morphology and viral status, in addition to clinical setting, as important information for lesion classification. In addition, the 2023 WHO recognizes a broader number of clinical scenarios in which these lesions arise, including not only traditional types of immune deficiency but also immune dysregulation<span>. With this classification it is hoped that new treatment strategies will be developed leading to better patient outcomes.</span></span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101167"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139104308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape 阵发性夜间血红蛋白尿:回顾患者的经验和治疗前景

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101158

Anem Waheed , Jamile Shammo , David Dingli

引用次数: 0

Contemporary tools for evaluation of hemostasis in neonates. Where are we and where are we headed? 评价新生儿止血的现代工具。我们在哪里，我们要去哪里?

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101157

Rozeta Sokou , Stavroula Parastatidou , Aikaterini Konstantinidi , Andreas G. Tsantes , Nicoletta Iacovidou , Daniele Piovani , Stefanos Bonovas , Argirios E. Tsantes

{"title":"Contemporary tools for evaluation of hemostasis in neonates. Where are we and where are we headed?","authors":"Rozeta Sokou , Stavroula Parastatidou , Aikaterini Konstantinidi , Andreas G. Tsantes , Nicoletta Iacovidou , Daniele Piovani , Stefanos Bonovas , Argirios E. Tsantes","doi":"10.1016/j.blre.2023.101157","DOIUrl":"10.1016/j.blre.2023.101157","url":null,"abstract":"<div><p><span>The assessment of hemostatic disorders<span><span><span> in neonates is crucial, but remains challenging for clinicians. Although the concept of developmental hemostasis<span> is widely accepted among hemostasis specialists globally, it is probably under-recognized by clinicians and laboratory practitioners. In parallel with age-dependent </span></span>hemostatic status maturation, comprehension of the differences between </span>normal values is crucial for the accurate diagnosis of potential hemorrhagic and thrombotic disorders of the vulnerable neonatal population. This review outlines the basics of developmental hemostasis and the features of the available </span></span>coagulation testing methods, with a focus on novel tools for evaluating the neonatal hemostatic profile. Common errors, issues, and pitfalls during the assessment of neonatal hemostasis are discussed, along with their impact on patient management. Current knowledge gaps and research areas are addressed. Further studying to improve our understanding of developmental hemostasis and its reflection on everyday clinical practice is warranted.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101157"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A 不折不扣的革命：新型延长半衰期第八因子替代产品和非替代制剂重塑了 A 型血友病的治疗格局

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101164

Hussien Ahmed H. Abdelgawad , Rachel Foster , Mario Otto

引用次数: 0

Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy? 通过抑制 E-选择素靶向血液恶性肿瘤：急性髓细胞性白血病治疗的甜蜜点？

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-02-28 DOI: 10.1016/j.blre.2024.101184

Geoffrey L. Uy , Daniel J. DeAngelo , Jay N. Lozier , Dennis M. Fisher , Brian A. Jonas , John L. Magnani , Pamela S. Becker , Hillard M. Lazarus , Ingrid G. Winkler

{"title":"Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?","authors":"Geoffrey L. Uy , Daniel J. DeAngelo , Jay N. Lozier , Dennis M. Fisher , Brian A. Jonas , John L. Magnani , Pamela S. Becker , Hillard M. Lazarus , Ingrid G. Winkler","doi":"10.1016/j.blre.2024.101184","DOIUrl":"10.1016/j.blre.2024.101184","url":null,"abstract":"<div><p>E-selectin, a cytoadhesive glycoprotein, is expressed on venular endothelial cells and mediates leukocyte localization to inflamed endothelium, the first step in inflammatory cell extravasation into tissue. Constitutive marrow endothelial E-selectin expression also supports bone marrow hematopoiesis via NF-κB-mediated signaling. Correspondingly, E-selectin interaction with E-selectin ligand (sialyl Lewis<sup>x</sup>) on acute myeloid leukemia (AML) cells leads to chemotherapy resistance in vivo. Uproleselan (GMI-1271) is a carbohydrate analog of sialyl Lewis<sup>x</sup> that blocks E-selectin binding. A Phase 2 trial of MEC chemotherapy combined with uproleselan for relapsed/refractory AML showed a median overall survival of 8.8 months and low (2%) rates of severe oral mucositis. Clinical trials seek to confirm activity in AML and mitigation of neutrophil-mediated adverse events (mucositis and diarrhea) after intensive chemotherapy. In this review we summarize E-selectin biology and the rationale for uproleselan in combination with other therapies for hematologic malignancies. We also describe uproleselan pharmacology and ongoing clinical trials.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"65 ","pages":"Article 101184"},"PeriodicalIF":7.4,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X24000171/pdfft?md5=6a37de75ade24871f4a8227183a16306&pid=1-s2.0-S0268960X24000171-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140141182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis 镰状细胞病术前输血的作用，系统回顾与荟萃分析

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-02-18 DOI: 10.1016/j.blre.2024.101183

Yasamin Abdu , Alaa Rahhal , Khalid Ahmed , Nada Adli , Mariam Abdou , Elrazi Awadelkarim Hamid Ali , Salam Al-Kindi , Mona Al Rasheed , Jaffer Altooq , Iheb Bougmiza , Mohamed A Yassin

{"title":"The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis","authors":"Yasamin Abdu , Alaa Rahhal , Khalid Ahmed , Nada Adli , Mariam Abdou , Elrazi Awadelkarim Hamid Ali , Salam Al-Kindi , Mona Al Rasheed , Jaffer Altooq , Iheb Bougmiza , Mohamed A Yassin","doi":"10.1016/j.blre.2024.101183","DOIUrl":"10.1016/j.blre.2024.101183","url":null,"abstract":"<div><p>This systematic review and meta-analysis aimed to provide guidance on preoperative blood transfusion strategies for patients with sickle cell disease (SCD). We included all randomized controlled and observational studies exploring the clinical outcomes of preoperative blood transfusion among patients with SCD compared to the conservative transfusion strategy until 14/09/2022.</p><p>Sixteen studies involving 3486 participants were analysed. The findings revealed a significantly higher bleeding rate in patients who received preoperative transfusion than those who followed a conservative strategy (RR = 4.32, 95% CI 1.75–10.68, <em>P</em> = 0.002, I2 = 0%). However, the two strategies had no significant differences in other clinical outcomes, such as acute chest syndrome, painful crisis, fever, neurological complications, thrombosis, ICU admission, and mortality. It is important to note that all the included studies had a moderate risk of bias. Preoperative transfusion in SCD was associated with a higher bleeding risk but a similar risk in other outcomes compared to conservative strategies. Notably, the increased bleeding risk observed seldom had clinical significance. We recommend individualizing management strategies, considering the overall positive impact of transfusions in reducing complications. Further high-quality studies are needed to refine recommendations.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"65 ","pages":"Article 101183"},"PeriodicalIF":7.4,"publicationDate":"2024-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X2400016X/pdfft?md5=dd69c17a7d33f03bd4c8da4aa597a962&pid=1-s2.0-S0268960X2400016X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139925876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Depression in patients with hematologic malignancies: The current landscape and future directions 血液系统恶性肿瘤患者的抑郁症：当前形势与未来方向

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-02-13 DOI: 10.1016/j.blre.2024.101182

Thomas M. Kuczmarski , Lizabeth Roemer , Oreofe O. Odejide

引用次数: 0

Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia β地中海贫血症成人患者的生活质量、情绪障碍和认知障碍。

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-02-08 DOI: 10.1016/j.blre.2024.101181

Maya Bizri , Rawan Koleilat , Nathalie Akiki , Reem Dergham , Alexandra Monica Mihailescu , Rayan Bou-Fakhredin , Khaled M. Musallam , Ali T. Taher

引用次数: 0

Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines 预防和处理接受 BTK 和 BCL-2 抑制剂治疗的慢性白细胞白血病 (CLL) 患者的感染性并发症，重点关注现行指南

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-02-01 DOI: 10.1016/j.blre.2024.101180

Malgorzata Mikulska , Chiara Oltolini , Emanuela Zappulo , Michele Bartoletti , Anna Maria Frustaci , Andrea Visentin , Candida Vitale , Francesca R. Mauro

{"title":"Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines","authors":"Malgorzata Mikulska , Chiara Oltolini , Emanuela Zappulo , Michele Bartoletti , Anna Maria Frustaci , Andrea Visentin , Candida Vitale , Francesca R. Mauro","doi":"10.1016/j.blre.2024.101180","DOIUrl":"10.1016/j.blre.2024.101180","url":null,"abstract":"<div><p>CLL is associated with an increased risk of infectious complications. Treatment with BTK or BCL-2 inhibitors does not seem to increase significantly the risk of opportunistic infections, but the role of combination therapies including BTK and/or BCL-2 inhibitors remains to be established. Various infectious complications can be successfully prevented with appropriate risk management strategies. In this paper we reviewed the international guidelines on prevention and management of infectious complications in patients with CLL treated with BTK or BCL-2 inhibitors. Universal pharmacological anti-herpes, antibacterial or antifungal prophylaxis is not warranted. Reactivation of HBV should be prevented in HBsAg-positive subjects. For HBsAg-negative/HBcAb-positive patients recommendations differ, but in case of combination treatment should follow those for other, particularly anti-CD20, agent. Immunization should be provided preferably before the onset of treatment. Immunoglobulin therapy has favourable impact on morbidity but not mortality in patients with hypogammaglobulinemia and severe or recurrent infections. Lack of high-quality data and heterogeneity of patients or protocols included in the studies might explain differences among the main guidelines. Better data collection is warranted.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"65 ","pages":"Article 101180"},"PeriodicalIF":7.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X24000134/pdfft?md5=ddd5ff0f153a77ef736e61e825a3b2c5&pid=1-s2.0-S0268960X24000134-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139670050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update: The molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas 最新进展：与病毒相关的高级别 B 细胞非霍奇金淋巴瘤的分子谱

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-01-20 DOI: 10.1016/j.blre.2024.101172

H. Witte , A. Künstner , N. Gebauer

{"title":"Update: The molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas","authors":"H. Witte , A. Künstner , N. Gebauer","doi":"10.1016/j.blre.2024.101172","DOIUrl":"10.1016/j.blre.2024.101172","url":null,"abstract":"<div><p>The vast spectrum of aggressive B-cell non-Hodgkin neoplasms (B-NHL) encompasses several infrequent entities occurring in association with viral infections, posing diagnostic challenges for practitioners. In the emerging era of precision oncology, the molecular characterization of malignancies has acquired paramount significance. The pathophysiological comprehension of specific entities and the identification of targeted therapeutic options have seen rapid development. However, owing to their rarity, not all entities have undergone exhaustive molecular characterization.</p><p>Considerable heterogeneity exists in the extant body of work, both in terms of employed methodologies and the scale of cases studied. Presently, therapeutic strategies are predominantly derived from observations in diffuse large B-cell lymphoma (DLBCL), the most prevalent subset of aggressive B-NHL. Ongoing investigations into the molecular profiles of these uncommon virus-associated entities are progressively facilitating a clearer distinction from DLBCL, ultimately paving the way towards individualized therapeutic approaches.</p><p>This review consolidates the current molecular insights into aggressive and virus-associated B-NHL, taking into consideration the recently updated 5th edition of the WHO classification of hematolymphoid tumors (WHO-5HAEM) and the International Consensus Classification (ICC). Additionally, potential therapeutically targetable susceptibilities are highlighted, offering a comprehensive overview of the present scientific landscape in the field.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"65 ","pages":"Article 101172"},"PeriodicalIF":7.4,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X24000055/pdfft?md5=b6fed54c1013340b4eafb52f8bc52263&pid=1-s2.0-S0268960X24000055-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139509835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0